• I. W. F. Hanham


Today a clinician who embarks on or specializes in cancer chemotherapy must have a basic knowledge of the mechanism of action of at least a dozen or more chemical agents which are active against cancer: and he must be aware of the importance of cell kinetics, dose schedules of those drugs, toxicity and its management, and the pharmacological background of the drugs he is using, particularly their mutual interactions and individual behavior. He must always be aware of the problems which can develop with individual patients.


Combination Chemotherapy Combination Regime Cytosine Arabinoside Hemorrhagic Cystitis Nitrogen Mustard 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ansfield, F. J., and Curreri, A. R. (1963). Further clinical comparison between 5-fluorouracil (5Fu) and 5-fluoro-2-deoxyuridine. Cancer Chemother. Rep. 32: 101.PubMedGoogle Scholar
  2. Brandt, K. (1970). Zentbl Gynak. 92: 233.Google Scholar
  3. Carter, S. K., and Friedman, M. (1974). Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat. Rev. 1: 001.CrossRefGoogle Scholar
  4. Costanzi, J. J., and Coltman, C. A. (1969). Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumours. Cancer Chemother. Rep. 53: 90.Google Scholar
  5. Cooper, R. C. (1969). Combination chemotherapy in hormone resistant breast cancer. Proc. Am. Assoc. Cancer Res. 10: 15.Google Scholar
  6. de Vita, V. T., Serpick, A. A., and Carbone, P. P. (1970). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann. Int. Med. 73: 881.Google Scholar
  7. Greenspan, E. M. (1966). Thiotepa, methotrexate, cyclophosphamide, 5-fluorouracil, and testosterone in advance breast cancer. J. Mount Sinai Hosp. 33: 1.Google Scholar
  8. Greenspan, E. M., Fieber, M. M., Geeson, L., and Edelman, S. (1963). Thiotepa and methotrexate chemotherapy of advanced breast cancer. J. Mount Sinai Hosp. 30: 246.Google Scholar
  9. Hanham, I. W. F. (1974). Chemotherapy in breast cancer. Proc. Royal Soc. Med. 67: 292.Google Scholar
  10. Hanham, I. W. F., Newton, K. A., and Westbury, G. (1971). Seventy five cases of solid tumours treated by a modified quadruple chemotherapy regime. Br. J. Cancer 25: 462.PubMedCrossRefGoogle Scholar
  11. Hellmann, K., and Burrage, Karen (1969). Control of malignant metastases by ICRF 159. Nature (London) 224: 273.CrossRefGoogle Scholar
  12. Hersh, E. M., Whitecar, J. P., McCredie, K. B., Bodey, G. P., and Freireich, E. J., (1971). Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukaemia. N. Eng. J. Med. 285: 1211.CrossRefGoogle Scholar
  13. Moertel, C. G., and Mays (1973). Therapy of advanced gastrointestinal cancer with the nitrosureas. Cancer Chemother. Rep. 4: 27.Google Scholar
  14. Newton, K. A., and Westbury, G. (1971). Indications for the treatment of cancer by regional chemotherapy. Geriatrics 26: 125.Google Scholar
  15. Pinkel, D., Walters, T., and Bushore, M. (1970). Identification of black children with acute lymphocytic leukemia (All) as high risk patients. Proc. Am. Assoc. Cancer Res. 11: 321.Google Scholar
  16. Price, L. A., and Goldie, J. H. (1971). Multiple drug therapy for disseminated malignant tumours. Br. Med. J. 4: 336.PubMedCrossRefGoogle Scholar
  17. Priestman, T. J., and Hanham, I. W. F. (1972). Results of 27 cases with hepatic metastases treated by combination chemotherapy. Br. J. Cancer 26: 466.PubMedCrossRefGoogle Scholar
  18. Salih, H., Flax, J., and Hobbs, J. R. (1972). In vitro oestrogen sensitivity of breast cancer tissue as a possible screening method for hormonal treatment. Lancet 1: 1198.PubMedCrossRefGoogle Scholar
  19. Salsbury, A. J., Burrage, Karen, and Hellman, K. (1970). Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. Br. Med. J. 4: 344.PubMedCrossRefGoogle Scholar
  20. Salsbury, A. J., Burrage, Karen, and Hellman, K. (1974). Analysis of the antimetastatic effect of ICRF 159. Cancer Res. 34: 843.PubMedGoogle Scholar
  21. Smith, J. P., and Rutledge, F. (1970). Chemotherapy in the treatment of cancer of the ovary. Am. J. Obstet. Gyn. 107: 69.Google Scholar
  22. South West Cancer Chemotherapy Group (1973). Chemotherapy of metastatic sarcomas using combinations with adriamycin. Symposium on Clinical Pharmacology, Jacksonville, Florida. Gottlieb, J. A., coordinator.Google Scholar
  23. Van Eden, E. B., Falkson, G., Van Der Merwe, A. M., Van Dyk, J. J., and Falkson, H. C. (1973). FIVB-A new combination of drugs in the treatment of cancer. S. Afr. Med. J. 47: 982.PubMedGoogle Scholar
  24. Wilson, R. E., Piro., A. J., Aliapoulios, M. A., and Moore, F. D. (1969). Evaluation of adrenalectomy and hypophysectomy in the treatment of metastatic cancer of the breast. Cancer 24: 1322.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1977

Authors and Affiliations

  • I. W. F. Hanham
    • 1
  1. 1.Oncology and RadiotherapyWestminster HospitalLondonEngland

Personalised recommendations